| |
Cases
|
Controls
|
|---|
|
Characteristic
|
n(%)
|
n(%)
|
|---|
|
Matched variables
|
|
Age at diagnosis (years)
|
|
<40
|
15(8%)
|
20(5%)
|
|
40-49
|
33(17%)
|
94(22%)
|
|
50-59
|
59(31%)
|
113(27%)
|
|
60-74
|
84(44%)
|
190(46%)
|
|
Race/ethnicity
|
|
White, non-Hispanic
|
146(76%)
|
326(78%)
|
|
White, Hispanic
|
7(4%)
|
11(3%)
|
|
Black
|
19(10%)
|
42(10%)
|
|
Asian
|
19(10%)
|
38(9%)
|
|
Surgery year
|
|
1985-1989
|
127(66%)
|
278(67%)
|
|
1990-1994
|
64(34%)
|
139(33%)
|
|
Adjuvant tamoxifen
|
|
No
|
134(70%)
|
281(67%)
|
|
Yes
|
57(30%)
|
136(33%)
|
|
Unmatched variables
|
|
Tumor size (cm)
|
|
≤ 1.0
|
40(21%)
|
128(31%)
|
|
1.1-2.0
|
84(44%)
|
187(45%)
|
|
2.1-4.0
|
63(33%)
|
96(23%)
|
|
>4.0
|
4(2%)
|
6(1%)
|
|
Tumor grade (differentiation)1
|
|
Well
|
21(11%)
|
123(29%)
|
|
Moderate
|
79(41%)
|
182(44%)
|
|
Poor
|
91(48%)
|
112(27%)
|
|
ER status from RT-PCR2
|
|
Positive
|
145(76%)
|
370(89%)
|
|
Negative
|
46(24%)
|
47(11%)
|
|
PR status from RT-PCR2
|
|
Positive
|
117(61%)
|
324(78%)
|
|
Negative
|
74(39%)
|
93(22%)
|
|
HER2 status from RT-PCR2
|
|
Positive
|
33(17%)
|
41(10%)
|
|
Negative
|
158(83%)
|
376(90%)
|
|
HOXB13:IL17BR
| | |
|
Low risk
|
71(37%)
|
222(53%)
|
|
High risk
|
120(63%)
|
195(47%)
|
|
MGI
| | |
|
Low risk
|
51(27%)
|
197(47%)
|
|
High risk
|
140(73%)
|
220(53%)
|
|
MGI+HOXB13:IL17BR
| | |
|
Low risk
|
51(27%)
|
197(47%)
|
|
Intermediate risk
|
50(26%)
|
108(26%)
|
|
High risk
|
90(47%)
|
112(27%)
|
|
BCI
| | |
|
Low risk
|
55(29%)
|
222(53%)
|
|
Intermediate risk
|
54(28%)
|
85(20%)
|
|
High risk
|
82(43%)
|
110(26%)
|
- 1Modified Bloom-Richardson grading criteria; 2performed by Genomic Health, Inc. (ER cut points ≤ 6.5 and >6.5 units; PR cut points <5.5 and ≥5.5 units; HER2 cut points <11.5 and ≥11.5 units).
